As normal HSPCs do not require BCAT1 and these cells have low BCAT1 expression, BCAT1 levels may define subsets of MPN patients that could exhibit BCAT1-driven therapeutic liabilities. The gene discussed is BCAT1; the disease is myeloproliferative neoplasm.